Veracyte to Acquire C2i Genomics, Expanding Diagnostics with AI-Powered MRD Testing

Date:

Veracyte, a leading genomics diagnostics company, has announced its acquisition of C2i Genomics in a definitive agreement. The acquisition aims to expand Veracyte’s diagnostics platform with the addition of whole-genome minimal residual disease (MRD) testing capabilities using artificial intelligence (AI) technology.

C2i Genomics specializes in MRD testing using liquid biopsies, specifically cell-free DNA (cfDNA) from blood samples. Their innovative MRD solution requires as little as 3-4 mL of blood or 1-2 mL of plasma and can deliver results within just two weeks. Compared to imaging and other molecular tests, C2i’s MRD testing has shown improved performance.

Under the agreement, Veracyte will pay $70 million in shares at closing and up to an additional $25 million based on future milestones over the next two years, payable in either Veracyte shares or cash.

One of the key advantages of C2i’s MRD testing is its ability to create circulating tumor DNA signatures using AI. By comparing the genomics of a patient’s tumor and blood, C2i’s solution eliminates the need for custom biomarker panels. When a patient undergoes a blood draw, whole-genome sequencing is performed to detect the circulating tumor DNA signature in the cfDNA.

Veracyte has been actively working on machine learning and AI algorithms for several years and has developed its own algorithms for noninvasive nasal swab tests for lung cancer. With the acquisition of C2i, Veracyte expands its AI capabilities and aims to track a tumor’s progression from early diagnosis to treatment and follow-up.

The integration of C2i’s technology into Veracyte’s platform will first be applied to a muscle-invasive bladder cancer MRD test. Veracyte plans to launch this test in the first half of 2026, leveraging C2i’s extensive research in the bladder cancer space and the clear path to reimbursement in this indication.

See also  Machine Learning Programs Predict Future Health of Aging Canadians, Canada

Marc Stapley, CEO of Veracyte, emphasizes the importance of evidence development in the cancer diagnostics industry. The acquisition of C2i, a whole-genome company, allows Veracyte to gather more clinical and genomic data, leading to deeper insights and increased adoption of their tests.

Veracyte’s long-term goal is to gain a significant share of the MRD market, which is projected to exceed $4 billion by 2032. By successfully launching and proving the clinical benefit of their tests in the markets they currently serve, Veracyte aims to expand into other indications, utilizing the knowledge gained from their ongoing efforts.

The acquisition of C2i Genomics strengthens Veracyte’s position as a leader in genomics diagnostics and enhances its capabilities in AI-powered MRD testing. With the potential to revolutionize cancer diagnosis and treatment monitoring, Veracyte is poised to make significant contributions to the field of precision medicine.

Frequently Asked Questions (FAQs) Related to the Above News

Please note that the FAQs provided on this page are based on the news article published. While we strive to provide accurate and up-to-date information, it is always recommended to consult relevant authorities or professionals before making any decisions or taking action based on the FAQs or the news article.

Share post:

Subscribe

Popular

More like this
Related

Obama’s Techno-Optimism Shifts as Democrats Navigate Changing Tech Landscape

Explore the evolution of tech policy from Obama's optimism to Harris's vision at the Democratic National Convention. What's next for Democrats in tech?

Tech Evolution: From Obama’s Optimism to Harris’s Vision

Explore the evolution of tech policy from Obama's optimism to Harris's vision at the Democratic National Convention. What's next for Democrats in tech?

Tonix Pharmaceuticals TNXP Shares Fall 14.61% After Q2 Earnings Report

Tonix Pharmaceuticals TNXP shares decline 14.61% post-Q2 earnings report. Evaluate investment strategy based on company updates and market dynamics.

The Future of Good Jobs: Why College Degrees are Essential through 2031

Discover the future of good jobs through 2031 and why college degrees are essential. Learn more about job projections and AI's influence.